Survival of patients with glioblastoma multiforme has not improved between 1993 and 2004: analysis of 625 cases

Tait, Matthew; Petrik, Vladimir; Loosemore, Alison; Bell, B. Anthony; Papadopoulos, Marios C.

doi:10.1080/02688690701449251

Cited by 73 publications

(61 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Approximately 400 pmol siRNA were delivered to the tumor mass in a mouse. Tumor size was measured with slide calipers twice every week, and the tumor volume was calculated according to the following formula: tumor volume (mm 3 ) ¼ length Â (width) 2 /2. Mice treated with HVJ-E-containing Eg5 siRNA, HVJ-E-containing negative control siRNA or PBS on day 7 were killed 24 h after treatment, then tumor tissues were collected for the following assays.…”

Section: Intradermal Tumor Model and Tumor Treatmentmentioning

confidence: 99%

“…The prognosis of glioblastoma is generally extremely poor, with a median survival time of o15 months. 1 In spite of advances in surgery, chemotherapy and radiotherapy over the past three decades, there has been no change in survival rates, 2,3 emphasizing a critical need to develop novel therapeutic approaches for this disease. This unfavorable prognosis is mainly because of its high propensity for tumor recurrence.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope

et al. 2009

View full text Add to dashboard Cite

Hemagglutinating virus of Japan envelope (HVJ-E) vector with inactivated replication-defective Sendai virus was originally developed as a versatile drug delivery system. Recently, we have shown the direct tumor-killing activity of HVJ-E itself without therapeutic molecules in prostate cancer cells. Although human glioblastoma cells were also sensitive to HVJ-E treatment, complete eradication was not achieved using HVJ-E alone. Here, to develop more effective therapeutic strategy of glioblastoma, we enhanced the anti-tumor activity by incorporating Short interfering RNA (siRNA) of mitotic motor protein Eg5 into HVJ-E. Treatment with HVJ-E-containing Eg5 siRNA induced monopolar spindle formation and resulted in cell-cycle arrest and apoptosis. When HVJ-E-containing Eg5 siRNA was directly injected into an intradermal tumor xenograft, all mice became tumor-free. Similar results were observed in the intracranial tumor xenografts. The survival time of treated mice was significantly prolonged when HVJ-E was used. Histological examination showed that tumors remained in the brain after treatment with HVJ-E-containing negative control siRNA, but no tumors were detected after treatment with HVJ-E-containing Eg5 siRNA. This remarkable anti-tumor response was likely due to a synergistic effect of Eg5 siRNA and HVJ-E. Thus, this combination shows promise as an attractive novel therapy for glioblastoma.

show abstract

Section: Intradermal Tumor Model and Tumor Treatmentmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The median survival of GBM patients is approximately one year. 16 The dismal prognosis and limited treatment choices give rise to the need for a novel and more efficient delivery route for chemotherapy against GBM. 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) is a commercial chemotherapeutic drug for brain malignancy because of its ability to penetrate the blood-brain barrier.…”

Section: Introductionmentioning

confidence: 99%

Improving thermal stability and efficacy of BCNU in treating glioma cells using PAA-functionalized graphene oxide

Yang²,

Hung³

et al. 2012

IJN

View full text Add to dashboard Cite

Background: 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), a commercial chemotherapeutic drug for treating malignant brain tumors, has poor thermal stability and a short half-life. Immobilization of BCNU on a nanocarrier might increase the thermal stability of BCNU and extend its half-life. Methods: Nanosized graphene oxide (GO) could be modified by polyacrylic acid (PAA) to improve the aqueous solubility and increase the cell penetration efficacy of the nanocarrier. PAA-GO intended as a drug carrier for BCNU was prepared and characterized in this study. The size and thickness of PAA-GO was investigated by transmission electron microscopy and atomic force microscopy, and the presence of PAA functional groups was confirmed by electron spectroscopy for chemical analysis and thermogravimetric analysis. BCNU was conjugated to PAA-GO by covalent binding for specific killing of cancer cells, which could also enhance the thermal stability of the drug. Results: Single layer PAA-GO (about 1.9 nm) with a lateral width as small as 36 nm was successfully prepared. The optimum drug immobilization condition was by reacting 0.5 mg PAA-GO with 0.4 mg BCNU, and the drug-loading capacity and residual drug activity were 198 µg BCNU/mg PAA-GO and 70%, respectively. This nanocarrier significantly prolonged the half-life of bound BCNU from 19 to 43 hours compared with free drug and showed efficient intracellular uptake by GL261 cancer cells. The in vitro anticancer efficacy of PAA-GO-BCNU was demonstrated by a 30% increase in DNA interstrand cross-linking and a 77% decrease in the IC 50 value toward GL261 compared with the same dosage of free drug. Conclusion: Nanosized PAA-GO serves as an efficient BCNU nanocarrier by covalent binding. This nanocarrier will be a promising new vehicle for an advanced drug delivery system in cancer therapy.

show abstract

“…Glioblastoma multiforme (GBM) is clinically and pathologically the most malignant type 42) . The median survival after diagnosis is approximately 11-12 months 27,42) .…”

Section: Introductionmentioning

confidence: 99%

“…Glioblastoma multiforme (GBM) is clinically and pathologically the most malignant type 42) . The median survival after diagnosis is approximately 11-12 months 27,42) . Many genetic alterations have been detected in this tumor type, and the most common genetic alterations are the tumor suppressor genes TP 39) , the cellular oncogene MDM2 45) , and the epidermal growth factor receptor (EGFR) 14) .…”

Section: Introductionmentioning

confidence: 99%

GRIM-19 Expression and Function in Human Gliomas

Jin

Jung

Jin

et al. 2010

J Korean Neurosurg Soc

View full text Add to dashboard Cite

Objective :We determined whether the expression of GRIM-19 is correlated with pathologic types and malignant grades in gliomas, and determined the function of GRIM-19 in human gliomas. Methods : Tumor tissues were isolated and frozen at -80˚C just after surgery. The tissues consisted of normal brain tissue (4), astrocytomas (2), anaplastic astrocytomas (2), oligodendrogliomas (13), anaplastic oligodendrogliomas (11), and glioblastomas (16). To profile tumor-related genes, we applied RNA differential display using a Genefishing TM DEG kit, and validated the tumor-related genes by reverse transcription polymerase chain reaction (RT-PCR). A human glioblastoma cell line (U343MG-A) was used for the GRIM-19 functional studies. The morphologic and cytoskeletal changes were examined via light and confocal microscopy. The migratory and invasive abilities were investigated by the simple scratch technique and Matrigel assay. The antiproliferative activity was determined by thiazolyl blue Tetrazolium bromide (MTT) assay and FACS analysis. Results : Based on RT-PCR analysis, the expression of GRIM-19 was higher in astrocytic tumors than oligodendroglial tumors. The expression of GRIM-19 was higher in high-grade tumors than low-grade tumors or normal brain tissue; glioblastomas showed the highest expression. After transfection of GRIM-19 into U343MG-A, the morphology of the sense-transfection cells became larger and more spindly. The antisensetransfection cells became smaller and rounder compared with wild type U343MG-A. The MTT assay showed that the sense-transfection cells were more sensitive to the combination of interferon-β and retinoic acid than U343MG-A cells or antisense-transfection cells; the antiproliferative activity was related to apoptosis.

show abstract

Survival of patients with glioblastoma multiforme has not improved between 1993 and 2004: analysis of 625 cases

Cited by 73 publications

References 19 publications

Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope

Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope

Improving thermal stability and efficacy of BCNU in treating glioma cells using PAA-functionalized graphene oxide

GRIM-19 Expression and Function in Human Gliomas

Contact Info

Product

Resources

About